CA2030581A1 - Preparations de pancreatine - Google Patents

Preparations de pancreatine

Info

Publication number
CA2030581A1
CA2030581A1 CA2030581A CA2030581A CA2030581A1 CA 2030581 A1 CA2030581 A1 CA 2030581A1 CA 2030581 A CA2030581 A CA 2030581A CA 2030581 A CA2030581 A CA 2030581A CA 2030581 A1 CA2030581 A1 CA 2030581A1
Authority
CA
Canada
Prior art keywords
pancreatin
mass
solvent
pancreatin preparations
preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2030581A
Other languages
English (en)
Other versions
CA2030581C (fr
Inventor
Gunther Atzl
Franz Langer
Herbert Polleres
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2030581A1 publication Critical patent/CA2030581A1/fr
Application granted granted Critical
Publication of CA2030581C publication Critical patent/CA2030581C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002030581A 1989-11-24 1990-11-22 Preparations de pancreatine Expired - Lifetime CA2030581C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT268889 1989-11-24
ATA2688/89 1989-11-24

Publications (2)

Publication Number Publication Date
CA2030581A1 true CA2030581A1 (fr) 1991-05-25
CA2030581C CA2030581C (fr) 2000-06-27

Family

ID=3538711

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002030581A Expired - Lifetime CA2030581C (fr) 1989-11-24 1990-11-22 Preparations de pancreatine

Country Status (13)

Country Link
US (2) US5674532A (fr)
EP (1) EP0436110B1 (fr)
JP (1) JP3025528B2 (fr)
KR (1) KR100229754B1 (fr)
AT (1) ATE102026T1 (fr)
AU (1) AU638784B2 (fr)
CA (1) CA2030581C (fr)
DE (1) DE69007055T2 (fr)
DK (1) DK0436110T3 (fr)
ES (1) ES2050340T3 (fr)
HK (1) HK102996A (fr)
PH (1) PH30058A (fr)
WO (1) WO1991007948A1 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5260074A (en) * 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
WO1996038169A1 (fr) * 1995-05-31 1996-12-05 Akzo Nobel N.V. Particules de pancreatine comprimees ayant un revetement gastro-resistant
CA2198317C (fr) * 1997-02-24 2003-01-07 Mouhsine El Abboudi Methode pour preparer de la pancreatine qui contient de faibles quantites residuelles de solvant organique et produit contenant cette derniere
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
KR100367659B1 (ko) * 2000-05-08 2003-01-14 주식회사 바이넥스 선택적 안정화제의 첨가에 따른 자가분해(autolysis)를 통한 고역가 판크레아틴의 제조방법
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US7153504B2 (en) * 2004-07-30 2006-12-26 Can Technologies, Inc. Stabilized pancreas product
HUE031042T2 (en) 2005-07-29 2017-06-28 Abbott Laboratories Gmbh Methods for producing pancreatin powder with low viral content
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
AU2008218595B2 (en) * 2007-02-20 2012-05-24 Allergan Therapeutics LLC Stable digestive enzyme compositions
US20090117180A1 (en) * 2007-02-20 2009-05-07 Giovanni Ortenzi Stable digestive enzyme compositions
WO2009109856A2 (fr) 2008-03-07 2009-09-11 Axcan Pharma Inc. Procédé pour détecter un parvovirus infectieux dans des préparations pharmaceutiques
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
ES2732453T3 (es) 2008-07-01 2019-11-22 Curemark Llc Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
EP2165717A1 (fr) 2008-08-27 2010-03-24 Nordmark Arzneimittel GmbH & Co.KG Procédé de réduction de la charge virale et microbienne d'extraits biologiques contenant de la matière solide
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CA3050530A1 (fr) 2009-01-06 2010-07-15 Galenagen, Llc Compositions et procedes pour le traitement ou la prevention d'infections par staphylococcus aureus et pour l'eradication ou la reduction de staphylococcus aureus sur des surfaces
JP2012514604A (ja) 2009-01-06 2012-06-28 キュレロン リミテッド ライアビリティ カンパニー 大腸菌(E.coli)による経口感染の治療または予防のための組成物および方法
WO2010085975A1 (fr) 2009-01-29 2010-08-05 Nordmark Arzneimittel Gmbh & Co. Kg Préparation pharmaceutique contenant des lipases d'origine bactérienne
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
PL2295039T5 (pl) 2009-08-28 2023-02-27 Nordmark Pharma Gmbh Sposób wytwarzania granulek zawierających pankreatynę, w szczególności mikrogranulek zawierających pankreatynę, oraz wytworzone tym sposobem granulki zawierające pankreatynę
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
UA111726C2 (uk) 2010-10-01 2016-06-10 Апталіс Фарма Лімітед Препарат панкреліпази низької сили з кишковорозчинним покриттям
DE202011000728U1 (de) 2011-03-30 2011-06-09 Nordmark Arzneimittel GmbH & Co. KG, 25436 Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets
EP2489349B1 (fr) 2011-02-17 2014-05-28 Nordmark Arzneimittel GmbH & Co.KG Granules de pancréatine, notamment micro-granules de pancréatine et leur procédé de fabrication
MX362974B (es) 2011-04-21 2019-02-28 Curemark Llc Compuestos para el tratamiento de alteraciones neuropsiquiatricas.
MX351014B (es) 2011-08-08 2017-09-28 Aptalis Pharma Ltd Metodo para la prueba de disolucion de composiciones solidas que contienen enzimas digestivas.
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US10184121B2 (en) 2013-06-28 2019-01-22 Allergan Pharmaceuticals International Limited Methods for removing viral contaminants from pancreatic extracts
CN106163544A (zh) 2013-08-09 2016-11-23 阿勒根制药国际有限公司 适于经肠施用的消化酶组合物
DE102015119006A1 (de) 2015-11-05 2017-05-11 Nordmark Arzneimittel Gmbh & Co. Kg Verfahren zur Reduzierung der Belastung von Pankreatin mit Mikroorganismen
DE102017104482A1 (de) 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Pharmazeutische Zusammensetzung umfassend Pankreatin und einen lipasehaltigen Überzug
AU2018250823A1 (en) 2017-04-10 2019-10-17 Curemark, Llc Compositions for treating addiction
FR3079146B1 (fr) * 2018-03-23 2020-04-17 Karim Ioualalen Formulation gastroprotectrice de complexes d’enzymes permettant de restaurer la fonction digestive.
WO2021250700A1 (fr) * 2020-06-10 2021-12-16 Kusum Healthcare Pvt. Ltd. Composition pharmaceutique de pancréatine
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3956483A (en) * 1968-10-24 1976-05-11 Wilson Pharmaceutical & Chemical Corporation Preparing pancreatin
FR2059978A1 (en) * 1969-08-20 1971-06-11 Sogeras Enteric coating of sensitive medicaments inp
JPS4946073B1 (fr) * 1970-04-08 1974-12-07
JPS57791B2 (fr) * 1973-11-23 1982-01-07
DE2512746C3 (de) * 1975-03-22 1980-04-24 Kali-Chemie Pharma Gmbh, 3000 Hannover Verfahren zur Herstellung von keimarmem, faserfreiem Pankreatin
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
DE2923279C2 (de) * 1979-06-08 1987-07-09 Kali-Chemie Pharma Gmbh, 3000 Hannover Verfahren zur Herstellung von Pankreatin-Pellets und diese enthaltende Arzneimittel
DE3377506D1 (en) * 1982-12-30 1988-09-01 Nordmark Arzneimittel Gmbh Process for obtaining pancreatin
EP0166315B1 (fr) * 1984-06-19 1989-08-23 BASF Aktiengesellschaft Microcomprimés cylindriques gastrorésistants à base de pancréatine
DE3445301A1 (de) * 1984-12-12 1986-06-12 Hoechst Ag, 6230 Frankfurt Pankreasenzympraeparate und verfahren zu deren herstellung

Also Published As

Publication number Publication date
PH30058A (en) 1996-11-08
AU6870191A (en) 1991-06-26
EP0436110B1 (fr) 1994-03-02
DK0436110T3 (da) 1994-06-20
DE69007055D1 (de) 1994-04-07
CA2030581C (fr) 2000-06-27
KR100229754B1 (ko) 1999-11-15
HK102996A (en) 1996-06-21
DE69007055T2 (de) 1994-08-25
US5861177A (en) 1999-01-19
EP0436110A1 (fr) 1991-07-10
KR910009282A (ko) 1991-06-28
WO1991007948A1 (fr) 1991-06-13
JP3025528B2 (ja) 2000-03-27
JPH03172181A (ja) 1991-07-25
ATE102026T1 (de) 1994-03-15
ES2050340T3 (es) 1994-05-16
AU638784B2 (en) 1993-07-08
US5674532A (en) 1997-10-07

Similar Documents

Publication Publication Date Title
PH30058A (en) Pancreation preparations
ES8603753A1 (es) Procedimiento de fabricacion de comprimidos efervescentes
HU902472D0 (en) Process for the production of freeze-dryed pharmaceutical products containing active agents
AU623967B2 (en) Process and spray drying apparatus for producing stable particle agglomerates
EP0793958A3 (fr) Procédé de préparation d'un composition contenant du fénofibrate
ZA889733B (en) Process for preparation of aloe products
AU8313287A (en) Process and apparatus for drying moist bulk material
EP0380931A3 (fr) Procédé de séchage en continu des gels hydrophiles polymères
AU5663480A (en) Solvent extraction process and apparatus
EP0606930A3 (en) Process for preparation of polymer particles, process for preparation of toner particles and particles prepared according to these processes.
IE41346B1 (en) Preparation of meat analogues
IE42073L (en) Tea extract
NO176645C (no) Fremgangsmåte ved fremstilling av stabil frysetörket polyhematoporfyrineter/ester-blanding
FR2613223B1 (fr) Forme galenique se presentant sous la forme de grains hydrosolubles, en particulier a base d'un extrait sec de ginkgo biloba, et son procede de preparation
EP0112563A3 (fr) Traitement par solvant de produits à base de protéines du plasma
IE780714L (en) Reclaiming elastomeric material
HU905897D0 (en) Process for the production of complexed medical preparations from ionogenic active agents
AU3022189A (en) Solvent extraction process
NZ234402A (en) Preparation of hyrolysed vegetable proteins comprising treatment with a protease, separating the soluble protein and treating same with acid
NO171013C (no) Fremgangsmaate til granulering av vannopploeslige gjoedningsmidler med hoeyt kiseritt-innhold
EP0315536A3 (fr) Esters polyaromatiques d'antibiotiques macrolidiques et lincosamidiques, leur procédé de préparation et compositions pharmaceutiques et cosmétiques les contenant
EP0568026A3 (fr) Comprimés de piroxicam et procédé pour leur préparation
SU542762A1 (ru) Способ выделени инвертазы из дрожжей
JPS5239503A (en) Method of drying metallurgical materials
SU1630040A1 (ru) Способ гранулирования лекарственных веществ

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry